LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesda
Related Questions
What new data or announcements are expected from the CEO and CFO at the conference?
How will the conference presentation affect NAGE's short-term trading volume?
What are the potential regulatory milestones for Niagen Bioscience's pipeline in 2024‑2025?
Could the conference reveal updates on product commercialization timelines that affect revenue forecasts?
Will any upcoming financial guidance or updates be disclosed that could move the stock?
What is the expected impact on the company's valuation based on projected growth in the NAD+ market?
How might the market react to any changes in financial outlook or cash‑burn guidance discussed at the fireside chat?
How does Niagen Bioscience's NAD+ platform compare to competitors in the anti‑aging space?
Could the conference provide insights into any upcoming M&A activity or strategic initiatives?
Is there any indication of new partnership or licensing deals to be announced?